The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital

EDUCATION

Research Projects

Project: Regulating macrophage 'eating' for cancer and pathogen control

Villadangos Group

The surface receptor SIRPα plays an important role in regulating phagocytosis by macrophages. This vital innate defence mechanism is vital against pathogens and tumours. We previously found that following sepsis in humans and mice, SIRPa surface levels decreased and this lead to reduced phagocytosis and loss of antimicrobial immunity. However, little is known about the molecular regulation of SIRPα and what causes it to go up or down. This project will use whole-genome wide CRISPR screens to investigate the molecular mechanism of SIRPα modulation. It will define new targets for therapeutics to boost macrophage function against infectious diseases and cancer. Further reading: Roquilly et al Nature Immunology, 2020. doi.org/10.1038/s41590-020-0673-x

Contact project supervisor for further
information and application enquiries

Project Supervisor

Dr Hamish McWilliam

Project Co-supervisor

Professor Jose Villadangos

Project availability
PhD/MPhil
Master of Biomedical Science
Honours

Villadangos Group

j.villadangos@unimelb.edu.au

6 vacancies

Themes
Immunology
Viral Infectious Diseases
Antimicrobial Resistance
Bacterial and Parasitic Infections
Cross Cutting Disciplines
Discovery Research
Clinical and health systems research

The Villadangos group studies the first event that triggers adaptive immune responses: the presentation of pathogen or tumour antigens to T cells by dendritic cells, B cells and macrophages. We are characterising the development, regulation and impairment of antigen presenting cells by pathogens, inflammatory mediators and tumours. We are also dissecting the biochemical machinery involved in antigen capture, processing and presentation. We use this knowledge to understand how T cell-dependent immunity is initiated and maintained, and apply it to design better vaccines and immunotherapies against infectious agents and cancer.


Villadangos Group Current Projects